BCDAW

Insider Trades

Name	Value	Action	Price	Current Price
Altman PeterDirector, Officer: President And CEO $1.4k1.5k shares BuyMay 20, 2026 $0.92 --
Altman PeterDirector, Officer: President And CEO $190200 shares BuyMay 19, 2026 $0.95 --
Altman PeterDirector, Officer: President And CEO $5.2k5.7k shares BuyMay 18, 2026 $0.92 --
Altman PeterDirector, Officer: President And CEO $5.2k5.1k shares BuyMay 15, 2026 $1.02 --
Altman PeterDirector, Officer: President And CEO $5.6k5k shares BuyApr 29, 2026 $1.11 --
Altman PeterDirector, Officer: President And CEO $492400 shares BuyApr 21, 2026 $1.23 --

Trade BCDAW

About BioCardia, Inc.

BioCardia, Inc. is a regenerative medicine enterprise, currently in the clinical development phase, dedicated to devising cell-based and cell-derived treatments for cardiac and pulmonary ailments. Its primary therapeutic offering is CardiAMP, an autologous mononuclear cell therapy system designed to address heart failure and persistent myocardial ischemia. In parallel, the company is advancing allogeneic cell therapies for various heart and lung diseases, including an investigational platform utilizing culture-expanded bone marrow-derived mesenchymal cells, which is presently in Phase I/II trials for ischemic heart failure. Beyond its therapeutic pipeline, BioCardia provides the Helix biotherapeutic delivery system, engineered to precisely inject treatments into the heart muscle via an internal helical needle, alongside Morph deflectable guides and sheaths. The company's operations are headquartered in Sunnyvale, California.

CEO: Peter A. Altman
IPO Date: Aug 2, 2019

Market Data

Open: $0.0062
High: $0.0063
Low: $0.0061
Volume: 18.7K
Avg Volume: 0
52W High: $0.0063
52W Low: $0.0061

Valuation

Market Cap: $10k
Enterprise Value: $5.1M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-7.4M
Revenue: $0
Net Income: $-8.2M
Cash: $2.5M
Debt: $528k

Events

EarningsSep 30

actual -0.11908